Immunicum announces new member of the Scientific Advisory Board
Anders Öhlén brings to Immunicum extensive experience as a senior executive in drug development and medical affairs from Kabi Pharmacia (now Pfizer), Astra, Aventis and Bristol-Myers Squibb, just to name a few and will be instrumental in expanding the depth and experience in clinical development that already exists at Immunicum. He has worked in several therapy areas and has been involved in all aspects of product life cycle management during his 30+ years of work in the healthcare and bio-pharma industries. Most recently, from 2010 to 2016, he was the CEO of the Swedish Pharmaceutical Insurance.
Read the press release here: Press release 160303 – Anders Öhlén
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805